Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biotie Buys Newron In Pain Deal; Price Brings Little Relief

This article was originally published in The Pink Sheet Daily

Executive Summary

Biotie's acquisition of pain-focused Newron for €38 million upfront reflects the trouble Newron was in - and the riskiness of the field.

You may also be interested in...



Germany's Merck Returns Safinamide To Newron, Merger With Biotie Now Under Review

The surprise announcement by Merck Serono to return all rights to safinamide to Italy's Newron has led to Biotie Therapies and Newron reviewing their plans to merge.

Germany's Merck Returns Safinamide To Newron, Merger With Biotie Now Under Review

The surprise announcement by Merck Serono to return all rights to safinamide to Italy's Newron has led to Biotie Therapies and Newron reviewing their plans to merge.

Lundbeck Invests £10M In CNS-Focused Proximagen

Lundbeck's support for Proximagen comes as biotechs struggle for survival in the high-risk CNS space.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel